Glycomine Inc.

HQ
San Carlos, California, USA
25 Total Employees
Year Founded: 2014

Similar Companies Hiring

Artificial Intelligence • Big Data • Healthtech • Machine Learning • Software • Biotech
4 Offices
918 Employees
Cloud • Healthtech • Social Impact • Software • Biotech
4 Offices
605 Employees
Artificial Intelligence • Big Data • Healthtech • Machine Learning • Analytics • Biotech • Generative AI
11 Offices
3775 Employees
We are developing GLM101, a novel substrate replacement therapy for PMM2-CDG, a congenital disorder of glycosylation.
Glycomine is developing orphan drugs for serious rare disorders of metabolism and protein misfolding for which no other therapeutic options exist. The company's approach is to use replacement therapies – substrates, enzymes, or proteins – and to target those molecules to clinically relevant cellular compartments. Glycomine’s lead drug candidate, GLM101, is a novel substrate replacement therapy in development to treat phosphomannomutase 2-congenital disorder of glycosylation (PMM2-CDG), a rare disease representing a critical unmet medical need.

Glycomine Inc. Offices

OnSite Workspace

Employees work from physical offices.

Typical time on-site: None
HQSan Carlos, California, USA